# Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

> **NCT04869137** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 26 (actual)

## Conditions studied

- Merkel Cell Carcinoma
- Neuroendocrine Carcinoma of the Skin
- Trabecular Carcinoma of the Skin

## Interventions

- **DRUG:** Lenvatinib Oral Product
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04869137
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-28
- **Primary completion:** 2025-09-13
- **Final completion:** 2026-09
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04869137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04869137, "Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04869137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*